| 2024-12-24 |
Week 4, December 2024: Evolving Hypotheses in Alzheimer's Research |
| 2024-12-17 |
Week 3, December 2024: Shifting Focus for Infectious Diseases |
| 2024-12-12 |
Partner with Biointron: Your CRO Solution for Custom Antibody Development |
| 2024-12-10 |
Week 2, December 2024: Inflammatory Conditions |
| 2024-12-03 |
Week 1, December 2024: Biparatopic Antibodies |
| 2024-12-01 |
November 2024: Antibody Reliability |
| 2024-11-26 |
Week 4, November 2024: The PD-1, PD-L1, and VEGF Train |
| 2024-11-19 |
Week 3, November 2024: Infant RSV |
| 2024-11-12 |
Week 2, November 2024: Reliability: Addressing Aggregation, Impurities, and Stability |
| 2024-11-05 |
Week 1, November 2024: Computationally Designed Antibody Therapeutics |
| 2024-10-31 |
October 2024: Computationally Designed Antibody Therapeutics |
| 2024-10-29 |
Week 5, October 2024: Anti-Amyloid Monoclonal Antibodies |
| 2024-10-22 |
Week 4, October 2024: Further than ADCs? |
| 2024-10-15 |
Week 3, October 2024: BARDA Funding |
| 2024-10-08 |
Week 2, October 2024: ADCs in Regulatory Review |
